Wellgistics Health, Inc. 8-K

What Happened
Wellgistics Health, Inc. (WGRX) announced on its Form 8-K that on March 6, 2026 it entered into an Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC. Under the agreement, Wellgistics is authorized to market, promote and distribute PharmTech’s "KARE Verify" benefits and eligibility verification product through the Company’s pharmacy, manufacturing and distribution channels, affiliated pharmacies and providers, and telemedicine/digital pharmacy platforms. The term is thirty-six (36) months unless earlier terminated.

Key Details

• Agreement date: March 6, 2026; press release furnished under Regulation FD on March 11, 2026 (Exhibit 99.1).
• Product: "KARE Verify" — a benefits and eligibility verification service.
• Revenue split: Net revenue from Product sales will be shared 50% to Wellgistics and 50% to Kare PharmTech.
• Term: 36 months (interim period) unless earlier terminated.

Why It Matters
The deal gives Wellgistics an immediate, contractual role in commercializing a healthcare verification product across its existing distribution and digital channels, creating a clearly defined revenue-sharing arrangement (50/50) for any net sales of KARE Verify. The filing does not include revenue forecasts, minimum guarantees, or other financial commitments, so investors should view this as a potential new revenue stream whose material impact will depend on future sales volumes and execution. The Company also issued a related press release on March 11, 2026.